Mary T. Szela Purchases 5,030 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela acquired 5,030 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were bought at an average cost of $5.03 per share, for a total transaction of $25,300.90. Following the completion of the acquisition, the chief executive officer now directly owns 439,249 shares of the company’s stock, valued at approximately $2,209,422.47. The trade was a 1.16 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

TriSalus Life Sciences Price Performance

Shares of TriSalus Life Sciences stock remained flat at $5.11 during trading hours on Friday. 61,315 shares of the company’s stock were exchanged, compared to its average volume of 28,061. The company’s fifty day simple moving average is $4.59 and its 200 day simple moving average is $4.75. The stock has a market cap of $155.80 million, a price-to-earnings ratio of -2.05 and a beta of 0.51. TriSalus Life Sciences, Inc. has a 1-year low of $3.50 and a 1-year high of $10.42.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Geode Capital Management LLC raised its position in shares of TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after purchasing an additional 62,542 shares during the last quarter. MSD Partners L.P. acquired a new position in shares of TriSalus Life Sciences during the 3rd quarter worth about $184,000. Vestcor Inc acquired a new position in shares of TriSalus Life Sciences during the 3rd quarter worth about $108,000. Virtu Financial LLC acquired a new position in shares of TriSalus Life Sciences during the 3rd quarter worth about $92,000. Finally, Walleye Capital LLC acquired a new position in shares of TriSalus Life Sciences during the 3rd quarter worth about $66,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on TLSI. Canaccord Genuity Group lowered their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Cantor Fitzgerald began coverage on shares of TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price target on the stock. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Roth Mkm reaffirmed a “buy” rating and issued a $11.00 price target on shares of TriSalus Life Sciences in a report on Friday, January 24th. Finally, Northland Securities began coverage on shares of TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target on the stock. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $11.79.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.